Company attributes
Other attributes
Guardant Health is a biotechnology company developing precision oncology treatments that is headquartered in Redwood City, California and was founded in 2012 by AmirAli Talasaz and Helmy Eltoukhy. The company offers a blood testing device that allows medical oncology professionals to gain a better understanding of the correct drugs to prescribe their cancer patients.
On February 11, 2014 Gaurdant Health announced completing their series A funding round with $10 million in funding from Sequoia Capital, OUP, Frank Malek, and Farzad Nazem. A number of undisclosed investors also participated in Guardant Health's series A funding round. The company's valuation at the time of receiving series A funding was not disclosed.
On April 22, 2014 Guardant Health announced raising over $30 million in series B funding from Khosla Ventures (lead investor), Sequoia Capital, Pear Ventures, and Signatures Capital. The co-founder and CEO of Gaurdant Health, Helmy Eltoukhy, made the following statement regarding the company's series B funding:
We are proud to welcome Khosla Ventures to the Guardant Health team as well as of the continued support of our existing partners and investors. The additional financing will allow Guardant Health to accelerate the expansion of its commercial operations to support growing demand and ensure a distinctively high level of service for our physicians and patients.
On February 3, 2015 Guardant Health announced raising $50 million in series C funding from Lightspeed Venture Partners (lead investor), SGH Capital, Sequoia Capital, Khosla Ventures, Formation 8, and Felicis Ventures. The completion of Guardant Health's series C round brought their total funding to date at $90 million. Helmy Eltoukhy, the CEO of Guardant Health, commented on what the company plans on doing with their series C funding by saying:
With this new funding, we can scale our operations to meet the significant demand for our biopsy-free blood test and help physicians identify effective treatments for their patients.
On January 7, 2016 Guardant Health announced raising $100 million in series D funding from OrbiMed (lead investor), Sequoia Capital, Pear Ventures, Lightspeed Venture Partners, Khosla Ventures, Hone Capital, Heritage Group, Formation 8, Felicis Ventures, Pejman Mar, and Laszlo Bock. In a Techcrunch interview the company told reporters the series D financing will primarily be used for developing their precision oncology technologies.
On May 11, 2017 Guardant Health announced raising $360 million in series E funding from SoftBank Vision Fund (lead investor), T.Rowe Price, Sequoia Capital, OrbiMed, Lightspeed Ventures Partners, Khosla Ventures, C.M. Capital Advisors, and 8VC. The company plans on using their series E funding to sequence the tumor DNA of over one million cancer patients. The co-founder and CEO of Guardant Health, Helmy Eltoukhy, made the following statement regarding the company's series E funding round:
We believe that conquering cancer is at its core a big data problem, and researchers have been data-starved. Our launch of the world’s first commercial comprehensive liquid biopsy sparked a boom in cancer data acquisition. Every physician who orders one of our tests and every patient whose tumor DNA we sequence add to this larger mission by improving our understanding of this complex disease. With this ambitious five-year effort, we intend to accelerate this progress and provide a much-needed infusion of data into the field.
